News

Overview

Normal

Press release year list 2023 2022 2021 2020 2019 2018

03/20/2023

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

02/22/2023

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

01/04/2023

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

Contact Us

investors@eternatx.com

Shareholder Services:

Website:
www.computershare.com

Phone:
1 (800) 736-3001 (U.S.)
1 (781) 575-3100 (non-U.S.)

Email:
web.queries@computershare.com

Regular Mail:
Computershare
P.O. Box 43006
Providence RI, 02940-3006

Courier Delivery:
Computershare
150 Royall St., Suite 101
Canton, MA 02021

Quick Links

SEC Filings
Information Request Form

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Eterna Therapeutics, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Eterna Therapeutics to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options *

Press Releases
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote

Unsubscribe